74 related articles for article (PubMed ID: 34526323)
1. PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups.
Karamitopoulou E; Andreou A; Pahud de Mortanges A; Tinguely M; Gloor B; Perren A
Cancer Immunol Res; 2021 Dec; 9(12):1439-1450. PubMed ID: 34526323
[TBL] [Abstract][Full Text] [Related]
2. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer.
Iwatate Y; Hoshino I; Yokota H; Ishige F; Itami M; Mori Y; Chiba S; Arimitsu H; Yanagibashi H; Nagase H; Takayama W
Br J Cancer; 2020 Oct; 123(8):1253-1261. PubMed ID: 32690867
[TBL] [Abstract][Full Text] [Related]
3. Emerging Prognostic and Predictive Factors in Pancreatic Cancer.
Karamitopoulou E
Mod Pathol; 2023 Nov; 36(11):100328. PubMed ID: 37714333
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma.
Singh L; Singh MK; Rizvi MA; Bakhshi S; Meel R; Lomi N; Sen S; Kashyap S
Cancer Immunol Immunother; 2020 Jun; 69(6):1087-1099. PubMed ID: 32100078
[TBL] [Abstract][Full Text] [Related]
5. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
Han G; Yang G; Hao D; Lu Y; Thein K; Simpson BS; Chen J; Sun R; Alhalabi O; Wang R; Dang M; Dai E; Zhang S; Nie F; Zhao S; Guo C; Hamza A; Czerniak B; Cheng C; Siefker-Radtke A; Bhat K; Futreal A; Peng G; Wargo J; Peng W; Kadara H; Ajani J; Swanton C; Litchfield K; Ahnert JR; Gao J; Wang L
Nat Commun; 2021 Sep; 12(1):5606. PubMed ID: 34556668
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
[TBL] [Abstract][Full Text] [Related]
7. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
Kraehenbuehl L; Weng CH; Eghbali S; Wolchok JD; Merghoub T
Nat Rev Clin Oncol; 2022 Jan; 19(1):37-50. PubMed ID: 34580473
[TBL] [Abstract][Full Text] [Related]
8. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
[TBL] [Abstract][Full Text] [Related]
9. Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion.
Nader GPF; Agüera-Gonzalez S; Routet F; Gratia M; Maurin M; Cancila V; Cadart C; Palamidessi A; Ramos RN; San Roman M; Gentili M; Yamada A; Williart A; Lodillinsky C; Lagoutte E; Villard C; Viovy JL; Tripodo C; Galon J; Scita G; Manel N; Chavrier P; Piel M
Cell; 2021 Sep; 184(20):5230-5246.e22. PubMed ID: 34551315
[TBL] [Abstract][Full Text] [Related]
10. PD-L1
Li Q; Zhou ZW; Lu J; Luo H; Wang SN; Peng Y; Deng MS; Song GB; Wang JM; Wei X; Wang D; Westover KD; Xu CX
Mol Ther; 2022 Feb; 30(2):621-631. PubMed ID: 34547468
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
Yang H; Zhu J; Xiao R; Liu Y; Yu F; Cai L; Qiu M; He F
Cancer Immunol Immunother; 2022 May; 71(5):1001-1016. PubMed ID: 34542660
[TBL] [Abstract][Full Text] [Related]
12.
Xu H; Yang G; Li W; Li J; Hao X; Xing P; Yang Y; Wang Y
Front Oncol; 2021; 11():713483. PubMed ID: 34540680
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
14. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
Hou P; Ma X; Yang Z; Zhang Q; Wu CJ; Li J; Tan L; Yao W; Yan L; Zhou X; Kimmelman AC; Lorenzi PL; Zhang J; Jiang S; Spring D; Wang YA; DePinho RA
Genes Dev; 2021 Oct; 35(19-20):1327-1332. PubMed ID: 34531315
[TBL] [Abstract][Full Text] [Related]
15. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene.
Hsu FC; Roberts NJ; Childs E; Porter N; Rabe KG; Borgida A; Ukaegbu C; Goggins MG; Hruban RH; Zogopoulos G; Syngal S; Gallinger S; Petersen GM; Klein AP
JAMA Oncol; 2021 Nov; 7(11):1664-1668. PubMed ID: 34529012
[TBL] [Abstract][Full Text] [Related]
16. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function.
Cabo M; Santana-Hernández S; Costa-Garcia M; Rea A; Lozano-Rodríguez R; Ataya M; Balaguer F; Juan M; Ochoa MC; Menéndez S; Comerma L; Rovira A; Berraondo P; Albanell J; Melero I; López-Botet M; Muntasell A
Cancer Immunol Res; 2021 Dec; 9(12):1476-1490. PubMed ID: 34580116
[TBL] [Abstract][Full Text] [Related]
17. Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition.
Junk D; Krämer S; Broschewitz J; Laura H; Massa C; Moulla Y; Hoang NA; Monecke A; Eichfeld U; Bechmann I; Lordick F; Seliger B; Kallendrusch S
Cell Death Discov; 2021 Sep; 7(1):264. PubMed ID: 34564709
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming.
Morrissey SM; Zhang F; Ding C; Montoya-Durango DE; Hu X; Yang C; Wang Z; Yuan F; Fox M; Zhang HG; Guo H; Tieri D; Kong M; Watson CT; Mitchell RA; Zhang X; McMasters KM; Huang J; Yan J
Cell Metab; 2021 Oct; 33(10):2040-2058.e10. PubMed ID: 34559989
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():732214. PubMed ID: 34557415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
